Mono-menotropins Versus rFSH Protocol on Embryo Quality

• Status: Completed
• Trial end date: 2017-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study is for couples pursuing in vitro fertilization (IVF) with preimplantation genetic screening (PGS) of embryos to achieve pregnancy. The objective of this clinical trial is to study the effect of mono-menotropins for COS versus recombinant follicle stimulating hormone (rFSH) on cleavage-stage and blastocyst embryo quality after IVF. Embryo quality parameters include conventional embryo grade, early embryo viability assessment (Eeva) time-lapse parameters, and chromosomal aneuploidy rates after PGS.

This pilot study is expected to significantly contribute to optimization of treatment regimens and stimulation protocols to optimize embryo quality.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Main Line Fertility Center
• Treatments: Follicle Stimulating Hormone; Hormones; Menotropins

Criteria

Inclusion Criteria:

• Patients undergoing IVF in an attempt to achieve pregnancy.

• Day 2-4 Follicle Stimulating Hormone (FSH) < 10 IU/ml, LH< 12 IU/ml, and estradiol <50 pg/ml on day 2-4 of menstrual cycle

• Antimullerian Hormone > 1.5

• Between 10 and 20 basal antral follicles on day 2-4 of the menstrual cycle

• Body weight >50 kg, with BMI > 18 and < 32 kg/m2

Exclusion Criteria:

• Smokers

• Polycystic ovarian disease

• Endometriosis greater than Stage I

• Testicular aspirated sperm

• Preimplantation Genetic Diagnosis (PGD) for single gene disorder

• Preimplantation Genetic Screening (PGS) banking cycles

• Donor Egg Cycles